Peripheral T-cell lymphomas (PTCLs) are insensitive to traditional chemotherapies which lack of effective treatments and have worse prognosis than B-cell lymphomas.Angiogenesis plays an essential role in the malignant tumor growth.Recently,studies have shown that the expression level of VEGF is related to the clinical characteristic and prognosis of PTCL.Novel drugs based on anti-angiogenic theory show curative effect in the preliminary clinical trials for the treatment of PTCL.

Neoplasms of the small intestine have no specific features at early stage,and the prognosis is poor.The 5-year survival rate of all the patients is about 30％ and the middle survival time is 19 months.The retrospective analysis shows that adjuvant chemotherapy after surgical resection might improve the disease free survival while the overall survival is not improved obviously.The patients who are at advanced stage or have regional lymph node metastasis may obtain benefits from adjuvant chemotherapy.Palliative chemotherapy may improve progress free survival and overall survival of patients who are at advanced stage.The therapeutic effect of patients at advanced stage using FOLFOX regimen ( 5-fluorouracil,calcium folinate and oxaliplatin ) is better compared with other regimens.The molecular targeted therapy of small intestine cancer is still in the study process and advanced studies are also needed for chemotherapy.

Fluorouracil,platinum and taxane are commonly used in the current chemotherapy of gastric cancer.The relationship between the key molecular biomarkers of mechanism of drug action and drug sensitivity has become a researchful hotspot,which is the prerequisite to achieve individualized treatment of gastric cancer.

A variety of molecular markers are related to the prognosis of gastric cancer,such as the the loss expression of AT rich interactive domain 1A (ARID1A),the overexpression of CD133 and survivin are releated to the incidence and poor prognosis of gastric cancer; leptin,CD44 and microRNA (miRNA) are releated to the invasion and metastasis of gastric cancer; the low expression of secreted protein acidic and rich in cysteine (SPARC) contributes to the angiogenesis of gastric cancer,but the relationship between SPARC and prognosis needs further study; the expression and gene polymorphism of excision repair cross-complementing 1 (ERCC1) may be useful for choice of medication in the treatment of gastric cancer.

Aggressive T cell non-Hodgkin lymphomas are a group of highly malignant tumors characterized by rapid progress and short survival.This is especially true for patients who have a poor response to treatment because of their drug resistance.Hence,to clarify the mechanism of this resistance will have important guiding significance in reversing drug resistance and improving poor prognosis of aggressive T cell nonHodgkin's lymphomas.

T-cell non-Hodgkin lymphoma is a group disease with unique clinical and pathological features. It is more aggressive and has lower chemotherapy sensitivity than B-cell lymphoma. In recent years, to search for effective treatment, novel agents such as gemcitabine, targeted therapy combined with chemotherapy and high-dose chemotherapy combined with hematopoietic stem cell transplantation are applied in the treatmentof T-cell non-Hodgkin lymphoma. And some progresses are achieved.

Objective To investigate the correlation between the expression of CD10,Bcl-6,VEGF with clinical characteristics and the prognosis in the primary gastrointestinal diffuse large B-cell lymphoma. Methods The clini-cal characteristics data of 66 patients with PGI-DLBCL were determined the levels of CD10,Bcl-6 and VEGF by immunohisto-chemical staining. Analyzed their correlation via Kaplan-Meier method and Log-rand test. Results Among those 66 patients,there were 36 cases(54. 5% )of primary stomach,while other 30 cases(45. 5% )were primary intestinal. 39 cases were GCB and 27 cases were non-GCB. The tumor stage and IPI were inverse propor-tion with the prognosis. The median progression-free-survival of GCB was 21. 50 months while non-GCB was 12. 00 months. The positive expression rate of Bcl-6 was 43. 9%(29 / 66)while that of CD10 was 34. 8%(23 / 66)and there were 29 cases(43. 9% )with positive expression of VEGF. Log-rank test revealed there was a positive correc-tion between the positive impression of CD10,Bcl-6 and PFS. On the contrary,the relationship between the ex-pressions of VEGF and PFS was negative. The expressions of CD10,Bcl-6 and VEGF were not correlated with clini-cal features. Cox multivariable analysis showed that the curative effect,the expressions of Bcl-6 and VEGF were in-dependent prognostic factors. Conclusion PGI-DLBCL is a highly invasive and heterogeneous malignancy. The stage of disease,the Hans classification,the level of IPI,the expression of CD10,Bcl-6 and VEGF may play im-portant roles in predicting the curative effect and the prognosis of the disease.

Clinical oncology is becoming more and more important as the tumor incidence increases year by year. According to the need of clinical teaching, some important contents in teaching should be emphasized. And some ideas should be pard attention to such as chronic disease needing long-period and long period of treatment of chronic tumor diseases, necessary pathlolgical diagnosis, in despensible evidence-based medicine, multidisciplinary treatment combined with individualized treatment, caring psychological problems and pain in cancer patients, recognizing tumor research progresses by way of molecular targeted therapy. Finally, some teaching methods to raise study interest in a flexible way were put forward.

Objective To investigate the characteristics of cisplatin resistance in human gastric cancer cell line SGC-7901 . Methods Single cell gel electrophoresis ( SCGE ) was used to measure the level of DNA damage and repair in gastric cancer cell line SGC-7901 and gastric cancer cisplatin resistance cell line SGC-7901/DDP by ob-serving the tail length. Morphological changes of SGC-7901 and SGC-7901/DDP were recorded to evalutate the differences between the two lines. The degree of migration of SGC-7901/DDP and SGC-7901 measured by cell wound scratch assay was used to estimate the ability of invasion. MTT assay was performed to determine the drug sensitivity, IC50 values and cross-resistance of SGC-7901/DDP treated with 5-FU, VP-16, ADM, TAX and LOHP separately. Results The level of DNA damage and repair in SGC-7901/DDP was higher than that in SGC-7901 ac-cording to the tail length of SCGE tests ,suggesting the relationship between cisplatin resistance and the abiity of DNA damage and repair. There was a much smaller volume in SGC-7901/DDP compared with SGC-7901,and clone aggregation always appeared in SGC-7901/DDP. Cell wound scratch assay showed that the migration of SGC-7901/DDP was weaker than that of SGC-7901. MTT showed the significant increase of IC50 and cross resitance in SGC-7901/DDP compared with SGC-7901 treated with 5-FU, VP-16, ADM, TAX and LOHP simultaneously. Conclu-sion The ability of DNA damage and repair in gastric cancer cisplatin resistance cell line SGC-7901 is enhanced significantly. The SGC-7901/DDP shows a notable promotion on multidrug resistance in vivo, and the migration of SGC-7901/DDP is weaker than that of SGC-7901 .

Chemotherapy is one of the primary treatment for malignant tumors.Platinum drugs as the most commonly used cycle non-specific clinical antitumor drugs show good curative effect in the clinical treatment of solid tumors,however,resistance or cross-resistance of theplatinum analogous has become one of the main obstacles for platinum and its analogous,which limits their clinical applications.miRNAs play an important role in biology,including cell proliferation,differentiation,apoptosis,stress tolerance,and physiological metabolism.There is a close relationship between miRNAs target gene regulation and tumor drug-resistance.This article is mainly about the role of miRNAs in tumor of platinum resistance.